214 related articles for article (PubMed ID: 36996606)
21. Cellular states are coupled to genomic and viral heterogeneity in HPV-related oropharyngeal carcinoma.
Puram SV; Mints M; Pal A; Qi Z; Reeb A; Gelev K; Barrett TF; Gerndt S; Liu P; Parikh AS; Ramadan S; Law T; Mroz EA; Rocco JW; Adkins D; Thorstad WL; Gay HA; Ding L; Paniello RC; Pipkorn P; Jackson RS; Wang X; Mazul A; Chernock R; Zevallos JP; Silva-Fisher J; Tirosh I
Nat Genet; 2023 Apr; 55(4):640-650. PubMed ID: 37012457
[TBL] [Abstract][Full Text] [Related]
22. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
23. CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
Liu T; Ma L; Song L; Yan B; Zhang S; Wang B; Zuo N; Sun X; Deng Y; Ren Q; Li Y; Zhou J; Liu Q; Wei L
Oral Oncol; 2022 Jun; 129():105858. PubMed ID: 35462155
[TBL] [Abstract][Full Text] [Related]
24. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Li C; Johnson DE
Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
[TBL] [Abstract][Full Text] [Related]
25. Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines.
Busch CJ; Becker B; Kriegs M; Gatzemeier F; Krüger K; Möckelmann N; Fritz G; Petersen C; Knecht R; Rothkamm K; Rieckmann T
Oncotarget; 2016 Jun; 7(24):35832-35842. PubMed ID: 27127883
[TBL] [Abstract][Full Text] [Related]
26. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.
Biktasova A; Hajek M; Sewell A; Gary C; Bellinger G; Deshpande HA; Bhatia A; Burtness B; Judson B; Mehra S; Yarbrough WG; Issaeva N
Clin Cancer Res; 2017 Dec; 23(23):7276-7287. PubMed ID: 28916527
[No Abstract] [Full Text] [Related]
27. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
28. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus predicts the outcome following concomitant chemoradiotherapy in patients with head and neck squamous cell carcinomas.
Duray A; Descamps G; Decaestecker C; Sirtaine N; Gilles A; Khalifé M; Chantrain G; Depuydt CE; Delvenne P; Saussez S
Oncol Rep; 2013 Jul; 30(1):371-6. PubMed ID: 23603900
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.
Liu C; Sadat SH; Ebisumoto K; Sakai A; Panuganti BA; Ren S; Goto Y; Haft S; Fukusumi T; Ando M; Saito Y; Guo T; Tamayo P; Yeerna H; Kim W; Hubbard J; Sharabi AB; Gutkind JS; Califano JA
Clin Cancer Res; 2020 Jun; 26(11):2693-2703. PubMed ID: 31932491
[TBL] [Abstract][Full Text] [Related]
32. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
33. HPV Enhances HNSCC Chemosensitization by Inhibiting SERPINB3 Expression to Disrupt the Fanconi Anemia Pathway.
Huang Z; Chen Y; Chen R; Zhou B; Wang Y; Hong L; Wang Y; Wang J; Xu X; Huang Z; Chen W
Adv Sci (Weinh); 2022 Nov; 10(1):e2202437. PubMed ID: 36382555
[TBL] [Abstract][Full Text] [Related]
34. Elevated intrinsic cancer stem cell population in human papillomavirus-associated head and neck squamous cell carcinoma.
Zhang M; Kumar B; Piao L; Xie X; Schmitt A; Arradaza N; Cippola M; Old M; Agrawal A; Ozer E; Schuller DE; Teknos TN; Pan Q
Cancer; 2014 Apr; 120(7):992-1001. PubMed ID: 24382806
[TBL] [Abstract][Full Text] [Related]
35. Deciphering head and neck cancer microenvironment: Single-cell and spatial transcriptomics reveals human papillomavirus-associated differences.
Lee H; Park S; Yun JH; Seo C; Ahn JM; Cha HY; Shin YS; Park HR; Lee D; Roh J; Heo HJ; Baek SE; Kim EK; Lee HS; Kim CH; Kim YH; Jang JY
J Med Virol; 2024 Jan; 96(1):e29386. PubMed ID: 38235919
[TBL] [Abstract][Full Text] [Related]
36. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
37. TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.
Wang L; Zhang P; Molkentine DP; Chen C; Molkentine JM; Piao H; Raju U; Zhang J; Valdecanas DR; Tailor RC; Thames HD; Buchholz TA; Chen J; Ma L; Mason KA; Ang KK; Meyn RE; Skinner HD
Oncogene; 2017 Feb; 36(6):820-828. PubMed ID: 27425591
[TBL] [Abstract][Full Text] [Related]
38. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
39. HPV and CSC in HNSCC cisplatin resistance.
Modur V; Thomas-Robbins K; Rao K
Front Biosci (Elite Ed); 2015 Jan; 7(1):58-66. PubMed ID: 25553363
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Psyrri A; Fortpied C; Koutsodontis G; Avgeris M; Kroupis C; Goutas N; Menis J; Herman L; Giurgea L; Remenár É; Degardin M; Pateras IS; Langendijk JA; van Herpen CML; Awada A; Germà-Lluch JR; Kienzer HR; Licitra L; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2213-2218. PubMed ID: 28651338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
